In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.
The following faculty have disclosed:
Edward H. Schuchman, MD, faculty for this educational event, received honoraria and advisory fees from Aceragen; and is a patent holder for Aceragen; and received ownership interest from Aceragen.
Paul Harmatz, MD, faculty for this educational event, received honoraria and advisory fees from Aeglea BioTherapeutics, Alexion Pharmaceuticals, Audentes, AVROBIO, Capsida, Chiesi USA, Inc., Denali, Enzyvant, Grace Science Foundation, Homology, Inventiva Pharma, JCR, Novel Pharma, Orchard Therapeutics, Paradigm, Renoviron, Saliogen, and Sobi, Inc.; and is a contract researcher from Allievex, Amicus Therapeutics, Inc., Ascendis, BioMarin Pharmaceutical Inc., Denali, Enzyvant, Idorsia, Inventiva Pharma, JCR, Orphazyme, Prevail, QED, RegenXbio, Sangamo, Sano and Genzyme US Companies, Sobi, Inc, and Takeda California, Inc.
V. Reid Sutton, MD, faculty for this educational event, received honoraria and advisory fees from Elevate Bio and Chiesi; and received research funds from Ultragenyx and Arcturus; and received ownership interest from Aceragen.
John Mitchell, MD, MSc, faculty for this educational event, has no relevant financial relationships with ineligible companies.